Omega-3 Index: The Cardiovascular Marker You Can Move

Most cardiovascular markers describe a situation you are largely stuck with, or one that takes a drug to change. The omega-3 index is unusual: it describes a structural property of your own cell membranes, it is set almost entirely by what you have eaten for the last few months, and it moves reliably when you change that. It is also one of the few markers where the average adult result is not merely suboptimal but a long way below the range associated with lowest risk.

What it measures, and why red cells

The omega-3 index is the combined amount of EPA and DHA expressed as a percentage of total fatty acids in the red blood cell membrane (Harris & von Schacky, Prev Med 2004). Not plasma — and that choice is the whole reason the marker is useful.

Plasma fatty acids reflect what you ate recently; a salmon dinner shows up there and washes out again. Membrane fatty acids are built into the phospholipid structure of the cell when it is made, and a red blood cell circulates for roughly four months before replacement. So a sample is a rolling record of what was available across the preceding three to four months — the same logic that makes HbA1c more informative than a single glucose reading. It also sets the rhythm: there is no point re-testing three weeks after a change, because most cells in circulation predate it.

Why the fat in a membrane changes anything

Physical structure. EPA and DHA are long and highly unsaturated, meaning kinked rather than straight. Membranes containing more of them are more fluid and deform more easily — which matters for red cells squeezing through capillaries, and for the receptors and ion channels embedded in every membrane, whose function depends on the physical environment around them. DHA is concentrated particularly heavily in neuronal and retinal membranes, which is why the marker keeps appearing in cognitive and visual research rather than only cardiac work.

Substrate competition. Omega-6 and omega-3 fatty acids compete for the same desaturase and elongase enzymes, and for the enzymes that convert them into signalling molecules. A diet dominated by omega-6 does not merely fail to supply omega-3 — it crowds it out of the pathway.

Signalling. EPA and DHA are the raw material for the specialised pro-resolving mediators — resolvins, protectins, maresins — which actively terminate an inflammatory response rather than merely failing to start one (Serhan, specialised pro-resolving mediators, PubMed). Resolution is an active process with its own chemistry, and its substrate comes from the pool this marker measures.

The ranges, and where most people sit

• Above 8% — the range associated with lowest cardiovascular risk in the cohort literature
• 4-8% — suboptimal, where most Western adults fall
• Below 4% — the highest-risk band

The average US adult sits around 4-6%, reflecting both low intake of oily fish and a food supply where the dominant added fats are omega-6 seed oils. Populations with high habitual fish intake sit considerably higher without supplementing anything. This is a good example of why a population reference range is not a target — if most of the population is deficient, the middle of the distribution is not where you want to be.

What higher levels are associated with

A higher index correlates with reduced cardiovascular events, lower rates of sudden cardiac death, slower cognitive decline, lower depression rates, reduced inflammatory markers and better visual function. The relationship with brain ageing has been shown with imaging as well as outcomes (Tan et al., Neurology 2012), and the association with total mortality holds across prospective cohorts (Harris et al., J Clin Lipidol 2018). The word doing the work there is correlates: these are observational associations, and they cannot by themselves prove that raising the marker lowers the risk.

The part usually left out

Large randomised trials of fish oil supplementation in unselected populations have mostly failed to demonstrate the cardiovascular event reduction the cohort data predicts (Abdelhamid et al., Cochrane review). That is a genuine tension and it deserves stating.

There are reasonable explanations, and they are explanations rather than proof. Most trials enrolled participants regardless of baseline status, so many already had adequate levels and nothing to gain. Most used a fixed dose rather than titrating to a target, and the relationship between intake and membrane content varies several-fold between individuals. And most measured the intervention as a dose swallowed rather than a level achieved — which, if the level is what matters, is like running a blood pressure trial without measuring blood pressure.

So the defensible position is narrower than the marketing: the index is a validated, modifiable risk marker, correcting a genuine deficiency is sensible, and supplementing on top of an adequate level has little evidence behind it. Which is precisely the argument for measuring rather than guessing.

Moving it, in practice

• Food first. Oily fish two or three times a week — salmon, sardines, mackerel, herring — is the most reliable route.
• Supplement the shortfall. EPA plus DHA in the region of 2-4 g daily is the usual working range for adults correcting a low index. What matters is the combined EPA and DHA on the label, not total fish oil weight, which is often several times larger.
• Take it with a meal containing fat — absorption is meaningfully better than on an empty stomach.
• Quality is not a marketing point here. These are highly oxidisable molecules and rancid product is common, so third-party testing for purity and oxidation is worth insisting on.
• Alternatives. Algal oil is the direct vegetarian source of DHA. Plant ALA from flax or walnuts converts only poorly in humans and is not an equivalent substitute.

Reducing omega-6 intake at the same time helps, because of the enzyme competition above — which overlaps with most of what improves the triglyceride/HDL ratio and hs-CRP anyway.

What to expect after you change something

Membrane turnover sets the timeline: a meaningful shift takes roughly three to four months, and the index keeps rising for some months after that before settling at a plateau determined by intake. Most adults starting around 4-5% can reach 8% or above within four to six months of consistent intake, though the dose required varies widely between individuals.

The sequence that works: test at baseline, change intake, re-test at three to four months, adjust the dose from the result rather than the label, then check annually. Nothing about how you feel tracks this marker reliably in the short term, so it is one to manage by measurement.

Bottom line

The omega-3 index measures EPA and DHA as a proportion of red cell membrane fatty acids, and because red cells live around four months it reports a three-to-four-month average rather than a snapshot. Membrane composition affects cell mechanics, receptor environment and the supply of molecules that actively resolve inflammation. Above 8% is the range associated with lowest risk; most Western adults sit at 4-6%. The honest caveat is that supplement trials in unselected populations have largely been neutral, most plausibly because they treated people who were not deficient and never measured what they achieved — an argument for testing, not for ignoring the marker. Oily fish two to three times a week, EPA plus DHA for the shortfall, and a re-test at three to four months is the whole protocol.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.